SRXH Form 4: Director David White Acquires Shares at $2.09, $1.23, $0.40

Rhea-AI Filing Summary

David Allan White, a newly appointed director of SRx Health Solutions, Inc. (SRXH), reported multiple stock acquisitions tied to his appointment. The Form 4 shows acquisitions on 04/24/2025, 05/01/2025, and 08/25/2025 totaling 344,975 shares held after the latest transaction and a separate block of 6,200 shares held directly. Prices per share for the reported purchases were $2.09, $1.23, and $0.40 respectively. The filing also reports 69,732 common stock purchase warrants exercisable on 07/07/2025 with a $0.62 exercise price expiring on 07/07/2028. The filer notes the reported shares reflect holdings as of his appointment as director on 04/24/2025.

Insights

Corporate Governance Analyst

Director appointment accompanied by equity grants and warrant coverage.

The reporting shows that David Allan White became a director on 04/24/2025 and immediately held common stock positions totaling 344,975 shares after subsequent purchases. These holdings include both direct shares and a distinct direct block of 6,200 shares, which is typical when equity is used to align new directors with shareholders.

Key governance dependencies include the vesting and transferability terms not disclosed on this Form 4; investors should note the presence of 69,732 warrants exercisable at $0.62 through 07/07/2028, which could dilute share count if exercised within that window.

Equity Compensation Specialist

Multiple purchase prices indicate staged or separate grant/purchase events.

The Form 4 lists acquisitions at $2.09, $1.23, and $0.40, plus warrants at $0.62. This pattern suggests distinct transactions or award tranches around the appointment date rather than a single lump grant.

Material items to watch include the 07/07/2025 exercisability of the warrants and the expiration on 07/07/2028; exercise activity would convert up to 69,732 shares into common stock, which is a concrete dilution cap tied to these derivative instruments.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

White David Allan

(Last) (First) (Middle)

12400 RACE TRACK ROAD

(Street)

TAMPA FL 33626

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SRx Health Solutions, Inc. [ SRXH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
04/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/25/2025		A		154,128	A	$0.4	344,975	D
Common Stock	05/01/2025		A		1,463	A	$1.23	190,847	D
Common Stock	04/24/2025		A		183,184	A	$2.09	189,384	D
Common Stock	04/24/2025		A		6,200	A	$2.09	6,200(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock Purchase Warrant	$0.62	07/07/2025		P		69,732		07/07/2025	07/07/2028	Common stock purchase warrant	69,732	$0.62	69,732	D

Explanation of Responses:

1. The reported shares represent holdings as of the date of appointment as a Director on 4/24/25.

	Carolina Martinez, Attorney-in- fact for David White	10/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did SRx Health (SRXH) director David White acquire per the Form 4?

The Form 4 reports Mr. White acquired common stock in several transactions and holds 344,975 shares after the latest reported purchase, plus a direct block of 6,200 shares.

Were any derivative securities reported for SRXH in this Form 4?

Yes. The filing reports 69,732 warrants exercisable on 07/07/2025 at an exercise price of $0.62, expiring on 07/07/2028.

What purchase prices are shown on the Form 4 for SRXH share acquisitions?

Reported purchase prices include $2.09, $1.23, and $0.40 for different acquisition dates.

When did David White become a director of SRx Health according to the filing?

The filer states the reported shares represent holdings as of his appointment as a director on 04/24/2025.

How could the reported warrants affect SRXH shareholders?

If the 69,732 warrants are exercised at $0.62, they would convert into the same number of common shares before the 07/07/2028 expiration, increasing the share count by that amount.